Top in hem/onc: Malignant brain tumor treatment, colorectal cancer in younger adults
Click Here to Manage Email Alerts
Researchers have made progress toward developing treatments for malignant brain tumors, but experts said it has been challenging to test multiple agents in clinical trials.
Healio spoke with neuro-oncologists and radiation oncologists about promising treatment approaches for malignant brain tumors, as well as vaccines and other advances in the pipeline. It was the top story in hematology/oncology last week.
In another top story, investigators identified a higher increase in distant early-onset colorectal adenocarcinoma among younger patients between the ages of 20 to 39 years. The highest proportions of distant-stage disease was among non-Hispanic Black and Hispanic populations.
Read these and more top stories in hematology/oncology below:
Novel approaches to malignant brain tumor treatment aim to overcome familiar challenges
Although therapeutic advances during the past decade have dramatically improved cancer outcomes overall, the outlook for patients with malignant brain tumors has remained poor. Read more.
Increase in distant-stage early colorectal cancer highest among younger age groups
Individuals aged between 20 and 39 years had the greatest burden of distant early-onset colorectal adenocarcinoma, according to a retrospective study published in Cancer Epidemiology, Biomarkers & Prevention. Read more.
From assessment to management, how best to care for cancer survivors at risk for lymphedema
Lymphedema — swelling in the limbs or trunk caused by excess fluid that can arise following cancer treatment — can be extremely detrimental to survivors’ quality of life. Read more.
Early screening after breast cancer treatment essential to reduce impact of lymphedema
Lymphedema occurs in around 20% of breast cancer survivors depending on the treatment course, but growing knowledge of risk factors and the importance of early screening can improve these odds. Read more.
FDA approves Kimmtrak for unresectable or metastatic uveal melanoma
The FDA approved tebentafusp-tebn for the treatment of adults with HLA-A*02:01-positive unresectable or metastatic uveal melanoma. Read more.